Enliven Therapeutics, Inc. (ELVN)
(Real Time Quote from BATS)
$21.00 USD
+0.80 (3.96%)
Updated Jun 7, 2024 03:54 PM ET
After-Market: $20.91 -0.09 (-0.43%) 4:12 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Price, Consensus and EPS Surprise
ELVN 21.00 +0.80(3.96%)
Will ELVN be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for ELVN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ELVN
3 Stocks in the Limelight on New Analyst Coverage
ELVN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for ELVN
Enliven Therapeutics’ ELVN-001 Poised for Success in CML Market Following Scemblix Data: A Buy Rating
Enliven Therapeutics to Present at Two Upcoming Investor Conferences
Strong Buy Rating for Enliven Therapeutics’ ELVN-001 Amid Favorable Market Dynamics
Short Report: GameStop, AMC Entertainment bears retreat further
Enliven Therapeutics: A Strong Buy on Market Dynamics and Scemblix’s Breakthrough Therapy Designation Impact